Certara (NASDAQ:CERT) Sets New 52-Week Low - Should You Sell?

Certara, Inc. (NASDAQ:CERT - Get Free Report)'s share price reached a new 52-week low on Friday . The stock traded as low as $9.96 and last traded at $10.02, with a volume of 102445 shares. The stock had previously closed at $10.53.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CERT shares. Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. Barclays dropped their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. Finally, UBS Group upgraded Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $15.92.

Certara Trading Down 5.4 %

The business has a fifty day simple moving average of $10.90 and a 200 day simple moving average of $13.46. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -49.80, a price-to-earnings-growth ratio of 5.46 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. During the same quarter in the previous year, the company earned $0.06 EPS. The business's revenue was up 10.7% on a year-over-year basis. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of the firm's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CERT. Blue Trust Inc. acquired a new position in Certara during the 2nd quarter worth approximately $26,000. Innealta Capital LLC bought a new stake in shares of Certara during the second quarter worth $36,000. KBC Group NV increased its holdings in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after buying an additional 1,584 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Certara in the 2nd quarter valued at $152,000. Finally, Algert Global LLC acquired a new stake in shares of Certara during the 2nd quarter valued at $156,000. Institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.